Lithium chloride regulates the proliferation of stem-like cells in retinoblastoma cell lines: a potential role for the canonical Wnt signaling pathway by Silva, Amanda K. et al.
Lithium chloride regulates the proliferation of stem-like cells in
retinoblastoma cell lines: a potential role for the canonical Wnt
signaling pathway
Amanda K. Silva,1 Hyun Yi,1 Sarah H. Hayes,2 Gail M. Seigel,2 Abigail S. Hackam1
1Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL; 2Department of Ophthalmology, SUNY
at Buffalo, Buffalo, NY
Purpose: Cancer stem cells are found in many tumor types and are believed to lead to regrowth of tumor mass due to
their  chemoresistance  and  self-renewal  capacity.  We  previously  demonstrated  small  subpopulations  of  cells  in
retinoblastoma tissue and cell lines that display cancer stem cell-like activities, including expression of stem cell markers,
Hoechst dye exclusion, slow cycling, and self-renewal ability. Identifying factors regulating stem cell proliferation will
be important for selectively targeting stem cells and controlling tumor growth. Wingless and Int1 (Wnt) signaling is an
essential  cellular  communication  pathway  that  regulates  proliferation  and  differentiation  of  non-neoplastic  stem/
progenitor cells in the retina and other tissues, but its role in cancer stem cells in the retinal tumor retinoblastoma is
unknown. In this study, we investigated whether the Wnt pathway activator lithium chloride (LiCl) regulates proliferation
of retinoblastoma cancer stem-like cells.
Methods: The number of stem-like cells in Weri and Y79 retinoblastoma cell line cultures was measured by 5-bromo-2-
deoxyuridine (BrdU) pulse-chase, immunohistochemistry, and quantitative polymerase chain reaction (PCR) for stem cell
marker genes. The cell lines were sorted into stem-like and non-stem-like populations by fluorescence-activated cell
sorting  (FACS),  using  an  antibody  against  the  stem  cell  marker  ATP-binding  cassette,  subfamily  G,  member  2
(ABCG2). Activated Wnt signaling was measured in the sorted cells by western blotting and immunolocalization of the
central mediator β-catenin.
Results: LiCl increased the number of stem-like cells, measured by BrdU retention and elevated expression of the stem
cell marker genes Nanog, octamer transcription factor 3 and 4 (Oct3/4), Musashi 1 (Msi1), and ABCG2. Sorted ABCG2-
positive stem-like cells had higher levels of β-catenin than ABCG2-negative non-stem cells, suggesting elevated canonical
Wnt signaling. Furthermore, stem cell marker gene expression increased after small interfering RNA (siRNA) knock-
down of the Wnt inhibitor secreted frizzled-related protein 2 (SFRP2).
Conclusions: These results indicate that the cancer stem-like cell population in retinoblastoma is regulated by canonical
Wnt/β-catenin signaling, which identifies the Wnt pathway as a potential mechanism for the control of stem cell renewal
and tumor formation in retinoblastoma tumors in vivo.
Solid tumors contain heterogeneous populations of cells
with different capacities for proliferation, differentiation, and
tumor initiation [1-3]. A population of cells termed cancer
stem cells was recently identified at low levels within many
types of cancers, including leukemias and cancers of the brain,
breast, lung, and prostate [4-7]. These cells have behaviors
reminiscent of non-neoplastic stem cells, are undifferentiated
yet retain the potential to differentiate, self-renew, and express
genes  involved  in  regulating  stem  cell  function.  Because
cancer  stem  cells  are  believed  to  be  chemoresistant  and
reestablish tumors, they have been proposed as important
targets for cancer therapy [8-10].
Retinoblastoma is a pediatric tumor of the retina observed
in approximately 1:15,000 live births [11]. A major challenge
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in the treatment of retinoblastoma is metastatic and secondary
tumors that often occur later in life. Current therapies often
lead to visual impairment and systemic complications. We
previously  identified  a  subpopulation  of  cells  in  two
retinoblastoma cell lines that express embryonic and neuronal
stem cell markers and exhibit label retention and self-renewal,
consistent with characteristics of cancer stem cells [12,13].
We also observed stem cell marker genes in retinoblastoma
tumor patients, suggesting that the existence of stem-like cells
is clinically relevant. Putative cancer stem-like cells were also
recently identified in primary retinoblastoma tissue using flow
cytometry to detect stem cell and retinal progenitor markers
[14].
The  cellular  signaling  pathways  that  control  the
proliferation  and  differentiation  of  stem-like  cells  in
retinoblastoma are unknown. A promising candidate pathway
is the Wingless and Int1 (Wnt) signaling pathway, which is
implicated in stem cell self-renewal and differentiation in
various cancers, and is a well described regulator of non-
Molecular Vision 2010; 16:36-45 <http://www.molvis.org/molvis/v16/a5>
Received 8 August 2009 | Accepted 7 January 2010 | Published 13 January 2010
© 2010 Molecular Vision
36neoplastic stem cells in many tissues, including retina, skin,
and gut [15-17]. Although generally oncogenic [18-20], we
and other researchers have observed a tumor suppressive role
for Wnt signaling [21-24].
Wnt ligands are secreted glycoproteins that bind to the
coreceptors  frizzled  (FZD)  and  low  density  lipoprotein
receptor-related protein 5 and 6 (LRP5/6). In the “canonical”
Wnt pathway, secreted Wnt ligands bind to their receptors,
which activates Disheveled (Dsh) and initiates a series of
molecular events that lead to increased β-catenin [25]. Nuclear
translocation of β-catenin allows it to bind to T-cell factor/
lymphoid enhancer binding factor (TCF/LEF) transcription
factors, which activates transcription of Wnt target genes,
including genes that control cell division, apoptosis, stem cell
phenotype, and metastasis [18,19,26]. In the absence of Wnt
ligands, β-catenin levels are maintained at low levels through
phosphorylation by the adenomatous polyposis coli (APC)-
axin-  glycogen  synthase  kinase  3  beta  (GSK3β)  protein
complex. In many tumors, mutational activation of APC and
axin, or constitutive activation of β-catenin, leads to elevated
Wnt signaling.
The  Wnt  signaling  pathway  regulates  viability  and
maintenance of non-neoplastic stem cells in the retina and
ciliary body [27-31]. In chick and mouse retina, canonical Wnt
signaling  regulates  proliferation  of  retinal  stem/progenitor
cells  and  maintains  them  in  an  uncommitted  state  and
suppresses  neuronal  differentiation  [30,32,33],  whereas  in
frogs, activating the Wnt pathway promotes progenitor cell
differentiation into neurons [28]. These data suggest that the
canonical Wnt pathway is a good candidate for regulating
proliferation of retinoblastoma stem-like cells. In this study,
we  characterized  the  response  of  stem-like  cells  in
retinoblastoma cell lines to the Wnt pathway activator lithium
chloride (LiCl).
METHODS
Immunostaining: The human retinoblastoma cell lines Weri-
RB27, a generous gift of Dr. John Ludlow, and Y79, obtained
from the American Type Culture Collection (Manassas, VA),
were cultured as described previously [13]. The cell lines were
treated with 0, 20, or 40 mM LiCl and incubated for 48 h. For
the proliferation assays in Figure 1 and Figure 2, control and
LiCl-treated cells were fixed for 10 min in cytospin solution,
which contained 72% isopropyl alcohol, 19% acetone, 7.6%
glycerin.  The  cells  were  then  centrifuged  onto  slides  for
immunocytochemical analysis. The slides were rinsed with
phosphate buffer solution (PBS, 137 mM NaCl, 2.7 mM KCl,
10 mM phosphate buffer), blocked with 2% BSA (BSA) in
PBS for 10 min then incubated in primary antibody for 1 h.
The primary antibody concentrations or dilutions used were
3  μg/ml  rabbit  anti-Musashi-1  (Msi1,  Neuromics,  Edina,
MN), 1 μg/ml rabbit anti-Ki67 antibody (Ab833, Abcam,
Cambridge, MA), 1:500 β-catenin (anti-rabbit from Sigma,
St.  Louis,  MO;  anti-mouse  from  BD  Transduction
Laboratories, San Jose, CA) and 1:200 dilution of mouse anti-
ATP-binding  cassette,  subfamily  G,  member  2  (ABCG2;
Abcam). After they were rinsed twice in PBS, the slides were
incubated  in  1  μg/ml  goat  anti-mouse  or  anti-rabbit
biotinylated secondary antibody (Zymed, San Francisco, CA)
for 30–45 min. Following two more washes in PBS, the slides
were incubated for 20 min in Vectastain ABC reagent (Vector
Laboratories, Temecula, CA), rinsed twice in PBS, and then
incubated with Diaminobenzidine (DAB) substrate for 5 min.
The slides were washed twice more in PBS, coverslipped with
Mowiol anti-fade mounting media (Sigma) and viewed on a
Nikon Eclipse E600 microscope. Eight equivalent fields were
counted for each concentration of LiCl used. For the β-catenin
localization  in  Figure  3A,  the  cells  were  fixed  in  4%
paraformaldehyde, blocked, and permeabilized using 2% goat
serum in 0.3% Triton X-100 in PBS and then incubated in
primary antibody. Following several PBS washes, the slides
were  incubated  in  1:600  dilution  of  secondary  antibody
(fluorescein isothiocyanate [FITC] or Texas red conjugated,
Invitrogen, Carlsbad, CA), washed and then viewed using a
fluorescent microscope (Zeiss Axiovert 200, Maple Grove,
MN). Images were captured with a digital camera (Axiocam,
Zeiss), and photographic and microscopic settings were kept
constant  for  comparisons  between  antibody  and  control
staining.  Eight  equivalent  fields  were  counted  for  per
experiment.
BrdU incorporation: Weri and Y79 cells were plated at a
density  of  3×105  cells/ml  and  incubated  with  10  μM  5-
bromo-2-deoxyuridine (BrdU) for one week with or without
LiCl. The cells were then washed three times with media and
incubated for an additional two weeks in the absence of BrdU.
The cells were collected and washed with 2× salt buffer, which
contained 1% BSA and 0.5% NaN3 in PBS. Cells were then
resuspended in half-salt buffer with 5% fetal bovine serum
(FBS), and fixed in ice-cold 70% ethanol. The cells were then
denatured with 2 N HCl for 20 min at room temperature and
then neutralized with 0.1 M sodium borate for 2 min. The
antibody incubations were performed with 1:50 anti-BrdU
antibody (BD Transduction Laboratories) for 16 h at 4 C,
followed by 1:300 AlexaFlour 488 donkey anti-mouse IgG, a
secondary antibody, for 30 min at room temperature. Prior to
flow  cytometry,  propidium  iodide  and  RNase  A  were
incubated with each cell pellet for 20 min, and the cells were
then filtered through a 35 micron nylon mesh strainer. Flow
cytometry was performed as described [24] using an LSR1
three laser flow cytometer (Becton–Dickinson). The percent
of  live  BrdU-positive  cells  was  calculated,  then  the
background calculated from secondary antibody alone was
subtracted,  and  the  samples  were  normalized  to  control
treatments without LiCl. Unpaired t-test or one-way ANOVA
and Tukey post-test were used for statistical analyses.
Cell sorting: The Weri and Y79 cells were pelleted, washed
with 2% BSA/PBS and resuspended in 1–2 ml BSA/PBS. The
resuspended  cells  where  incubated  with  anti-ABCG2
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37antibody (anti-ABCG2-BXP21, Covance) at 4 °C for 20 min,
with gentle shaking every 2 min. To control for specificity,
the isotype negative control mouse IgG2a antibody (R&D)
was used in parallel experiments. The cells were then washed
with 10 ml BSA/PBS, resuspended in 1 ml BSA/PBS, and
incubated with 5 µl of goat anti-mouse FITC-conjugated, a
secondary  antibody  (Sigma  F0257)  at  4  °C  for  20  min.
Following  several  additional  washes,  the  cells  were
resuspended in BSA/PBS at 2–3 million cells/ml for sorting
by  FACS  using  a  FACSAria  III  apparatus  (Becton-
Dickinson). The sorted cells were pelleted and then processed
for western blotting or RNA analysis, as described previously
[24]. For western blot analysis the cells were first lysed in
buffer containing proteinase inhibitors (50 mM Tris, pH 7.4,
150 mM NaCl, 1% EDTA, 1% NP-40), and then 20 μg of
protein was resolved in 10% SDS–PAGE gels using Tris-
Glycine  buffer.  The  proteins  were  transferred  onto
polyvinylidene fluoride (PVDF) membranes and probed using
the  anti-β-catenin  antibody  described  above.  For  RNA
analysis, Trizol reagent (Invitrogen) was used to extract total
RNA  from  the  pelleted  sorted  cells,  according  to  the
manufacturer's  directions  [34].  Briefly,  the  pellet  was
homogenized  in  Trizol,  followed  by  incubation  with
chloroform  and  centrifugation  to  allow  phase  separation.
RNA  was  precipitated  from  the  aqueous  phase  using
isopropanol,  washed  with  75%  ethanol,  dried  and  then
resuspended in water.
Quantitative  PCR:  Total  RNA  was  extracted  from  the
retinoblastoma  cells  using  Trizol  reagent  (Invitrogen),  as
described above. One microgram of RNA was treated with
DNase (Ambion, Austin, TX) and cDNA was synthesized
using  Thermoscript  (Invitrogen).  Quantitative  PCR  was
performed using the iCycler thermocycler (BioRad, Hercules,
CA) with primers that were specific to the gene of interest and
crossed intron-exon boundaries. The primers for Nanog [35]
and Oct3/4 are listed in Table 1. Relative transcript levels of
each gene were calculated using the delta-delta Ct method,
using a housekeeping gene as the reference gene.
siRNA  transfection:  The  Silencer  small  interfering  RNA
Starter Kit (siRNA; Ambion) was used to reduce secreted
frizzled-related  protein  2  (SFRP2)  expression.  siRNAs
corresponding  to  SFRP2  and  GAPDH,  and  a  scrambled
siRNA  for  the  negative  control,  were  purchased  from
Ambion. Two independent siRNAs were used against SFRP2:
Sfrp2(A)  siRNA  (ID#  s12716;  sense  5′-CCA  AGA  GCA
AGA CCA UUU Att-3′, anti-sense 5′- UAA AUG GUC UUG
CUC UUG Gtc-3′) and Sfrp2(B) siRNA (ID# s12717; sense
5′-CAU CAA CCG AGA UAC CAA Att-3′, anti-sense 5′-
UUU GGU AUC UCG GUU GAU Gta-3′). Weri cells were
plated in a six-well plate at 1.5×105 cells/ml and incubated in
2% FBS/RPMI 1640 media before transfection. The siPORT
reagent (Ambion) was used for the transfections, according to
the  manufacturer’s  protocol.  Transfection  efficiency  in
control transfections was approximately 40%. Briefly, 5 μl of
siPORT was diluted in 295 μl serum-free media and incubated
for 10 min at room temperature. Next, 12.5 pmol of Sfrp2
siRNA  was  diluted  in  serum-free  media  and  mixed  with
diluted siPORT, incubated for 10 min then added to the cells
for 24 h. The cells were collected for RNA extraction, and
quantitative PCR was performed as described in the previous
section.
RESULTS
Subpopulations of cells in the retinoblastoma cell lines Weri
and Y79 and in primary retinoblastoma tissue were identified
with  characteristics  of  stem  cells,  including  marker  gene
expression, Hoechst dye exclusion, and BrdU label retention
[12-14]. To test the hypothesis that the Wnt signaling pathway
regulates proliferation of these stem cell-like cells, we induced
Wnt signaling in the Weri and Y79 retinoblastoma cell lines
by treating with 20 mM and 40 mM LiCl. LiCl activates Wnt
signaling  by  inhibiting  GSK3β,  leading  to  β-catenin
stabilization and translocation into the nucleus. LiCl was used
in this study because it had a greater phenotypic effect on
retinoblastoma cell lines than the canonical Wnt ligand Wnt3a
[24].
Stem-like cells in Weri and Y79 cell lines were detected
by  immunoreactivity  to  the  stem  cell  marker  proteins
ABCG2  and  Msi1.  As  shown  in  Figure  1A,  the  baseline
number of cells expressing these proteins in untreated controls
was 10–20 cells per 40× field. LiCl treatment significantly
increased the number of ABCG2-positive cells up to 50 cells
per  field  in  both  Weri  and  Y79  cell  lines.  LiCl  also
significantly increased the number of cells that expressed the
stem cell marker protein Msi1 to approximately 80 cells per
field.
TABLE 1. PRIMERS USED FOR SYBR-GREEN QUANTITATIVE PCR ANALYSIS
Gene Primer (5′-3′) Product size
Nanog F: CTAAGAGGTGGCAGAAAAACA 101 bp
R: CTGGTGGTAGGAAGAGTAAAGG
Oct3/4 F: ACATCAAAGCTCTGCAGAAAGAACTC 126 bp
R: CTGAATACCTTCCCAAATAGAACCC
F represents the sense primer; R represents the antisense primer. The size of the amplified product is indicated.
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38The expression of two additional stem cell marker genes,
Nanog and Oct3/4, was analyzed. Quantitative PCR was used
because of high background in the immunostaining for these
two proteins. LiCl increased Nanog and Oct3/4 expression in
the cell lines (Figure 1B). All four of the genes in Figure 1 had
significantly greater expression with 40 mM LiCl compared
with 20 mM LiCl. Therefore, LiCl increased the expression
and immunoreactivity of multiple stem cell genes, indicating
that LiCl expands the population of stem-like cells in the Weri
and Y79 retinoblastoma cell lines.
We next used a functional assay to quantify the effect of
LiCl on proliferation of the stem-like cells. A commonly used
functional marker of cancer stem cells is slow cycling [13],
which may cause chemoresistance by allowing time for the
cells to repair damaged DNA [8]. Slow cycling can be detected
by retention of BrdU in a pulse-chase experiment. Y79 cells
were  used  in  this  experiment  because  they  had  higher
expression of the stem cell marker genes than Weri cells in
Figure 1B, predicting a greater effect with BrdU. To determine
whether LiCl alters the number of cells that retain BrdU, we
incubated  Y79  cells  with  LiCl  and  BrdU  and  used  flow
cytometry to quantitate the number of live cells that were
BrdU-positive.  As  shown  in  Figure  2,  LiCl  treatment
significantly increased the number of slow cycling cells by
approximately  fourfold,  indicating  an  expansion  of  the
number of stem-like cells in the culture.
Reduced  proliferation  rate  can  also  be  measured  by
detection of the proliferation marker Ki67. We quantified the
effect  of  LiCl  on  the  number  of  cells  that  were
immunoreactive  for  the  Ki67  protein  by  comparing  to
untreated  cultures.  LiCl  treatment  of  Weri  and  Y79  cells
significantly decreased the number of Ki67-positive cells to
Figure 1. LiCl expands the population of
stem-like  cells  in  the  Weri  and  Y79
retinoblastoma  cell  lines.  A:  LiCl
significantly  increased  the  number  of
ABCG2  and  Musashi-1  (Msi-1)
immunoreactive  cells.  Weri  and  Y79
human retinoblastoma cells were treated
with 0, 20, and 40 mM LiCl for 48 h and
then  immunostained.  The  number  of
cells  expressing  ABCG2  (left)  or
Musashi-1 (Msi-1; right) were counted.
The differences between 20 mM LiCl
and  control,  and  40  mM  LiCl  and
control,  were  significant  at  a  p-
value<0.001 (*). Each experiment was
repeated eight times. B: LiCl increased
the expression of stem cell marker genes
Nanog  and  Oct3/4.  QPCR  was
performed on Weri and Y79 cells treated
with  20  mM  or  40  mM  LiCl.  LiCl
increased Nanog and Oct3/4 levels, and
there  was  significantly  greater
expression with 40 mM LiCl treatment
compared  with  20  mM  LiCl  at  a  p-
value<0.05,  indicated  by  the  asterisk.
Each  experiment  was  repeated  three
times.
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3910 cells/field in LiCl-treated cultures from 35 cells/field in
control cultures (Figure 3).
Wnt  signaling  maintains  the  stem  phenotype  of  non-
neoplastic stem cells in the mammalian retina [30,32,33].
Therefore, we next asked whether the stem-like cells in the
retinoblastoma cell lines have higher levels of endogenous
Wnt  signaling  than  the  nonstem  cells.  To  address  this
question, Wnt signaling levels were measured using western
blotting for β-catenin. Increased β-catenin levels is a well
established marker of canonical Wnt pathway activation. Our
previous study in Weri and Y79 cell lines demonstrated low
β-catenin levels that could be induced by exogenous Wnt
Figure 2. The number of slow cycling cells was increased by LiCl.
Y79 cells were incubated with LiCl and pulse-chased with BrdU for
a total of 3 weeks. The number of live cells retaining BrdU was
measured by flow cytometry. The percent of gated live BrdU+ cells
was  calculated  and  normalized  to  untreated  cells  and  there  was
significantly greater BrdU+ cells in the LiCl-treated samples at a p-
value<0.05, indicated by the asterisk. Each experiment was repeated
three times.
Figure 3. LiCl decreased the proliferative index of the retinoblastoma
cell lines. Weri and Y79 retinoblastoma cells were treated with 0, 20,
40 mM LiCl for 48 h and then immunostained. LiCl significantly
decreased the number of Ki67 immunoreactive cells (n=8).
pathway activators, indicating that the canonical Wnt pathway
was downregulated but that it is intact and functional [24].
We next used immunodetection to quantify the number
of stem-like cells with Wnt signaling using Msi1 as a stem cell
marker (Figure 5). We found that 30.6% (SD±2.2) of Msi1-
positive cells contained nuclear β-catenin in the Weri cell line,
and 28.2% (SD±3.4) cells contained nuclear in the Y79 cell
line. In contrast, veryy few Msi1-negative cells in the Weri
(1.31%.  SD±0.55)  and  Y79  (1.21%,  SD±0.49)  contained
nuclear β-catenin in both cell lines (p<0.001 compared with
Msi1-positive cells, n=5), indicating that retinoblastoma cells
with active Wnt signaling were more likely to be stem cells.
The secreted Wnt inhibitor SFRP2 was recently shown to
be a differentiation-promoting gene in retinal stem/progenitor
cells in rat [36]. Reduction of SFRP2 levels by activating the
Notch  signaling  pathway  leads  to  disinhibition  of  Wnt
signaling, increased proliferation of stem/progenitor cells and
decreased  expression  of  proneural  genes  [36].  Therefore,
SFRP2 is an attractive candidate molecule for mediating stem
cell proliferation by LiCl/Wnt signaling in retinoblastoma cell
lines.  Quantitative  PCR  on  LiCl-treated  cell  lines
demonstrated that SFRP2 was reduced by up to sixfold in Weri
and fourfold in Y79 cells (Figure 6A).
To determine whether SFRP2 regulates retinoblastoma
stem cells, we experimentally reduced SFRP2 levels, using
siRNA, and employed expression of Nanog and Oct3/4 as
markers of the stem cell phenotype. Weri cells were used in
this  experiment  because  they  had  a  higher  transfection
efficiency than Y79 cells. As shown in Figure 6B, reducing
SFRP2 levels by siRNA transfection (average reduction was
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The stem-like cells in Weri and Y79 cell lines represent
approximately 4% of the total cell population [13]. Therefore,
to compare Wnt signaling in stem-like cells with nonstem
cells, we first sorted the cells using flow cytometry with the
stem cell marker protein ABCG2. Western blotting for β-
catenin on the ABCG2-positive stem cells from Weri cultures
demonstrated 4.1-fold (SD±1.2) higher β-catenin levels than
the ABCG2-negative cells (p<0.05, n=3), indicating greater
canonical Wnt signaling in the stem-like cells (Figure 4A).
Examples of double-staining of ABCG2 and β-catenin, and
Msi1 and β-catenin, are shown in Figure 4B-E. Detection of
the stem cell markers were rare events in unsorted cells in
relation to the entire culture. Stem cell-immunoreactive cells
tended to appear in clusters, possibly due to mother-daughter
cell proximity.
To identify a potential mechanism for upregulated β-
catenin levels in ABCG2-positive stem cells, we compared
levels of canonical Wnt signaling receptors using quantitative
PCR  analysis.  As  shown  in  Figure  4G,  there  was  higher
expression of the receptors LRP6, Frizzled 3 (Fz3), Fz4, and
Fz6 in the ABCG2-positive stem-like cells than in ABCG2-
negative  nonstem  cells.  Interestingly,  there  were  also
differences in receptor expression between the cell lines.Figure 4. Elevated canonical Wnt signaling in flow-sorted retinoblastoma cancer stem-like cells. A: Weri cells were sorted by flow cytometry
using an antibody against the stem cell marker ABCG2. RNA and protein were then extracted from the ABCG2-positive and ABCG2-negative
cells. Western blotting on sorted ABCG2+ stem cells showed higher β-catenin levels, indicating higher canonical Wnt signaling in the stem
cells (n=3, p=0.048). β-catenin levels were normalized to β-actin, and are expressed as a ratio of the respective ABCG2-negative cells. B-F:
Representative images showing the immunoreactivity of the stem cell markers ABCG2 and Msi1, and the canonical Wnt signaling mediator
β-catenin in the retinoblastoma cell lines Weri and Y79. In the top right panels, ABCG2 immunoreactivity is red and β-catenin is green. In
the top left panels, Msi1 immunoreactivity is green and β-catenin is red. The bottom panels show the negative controls, in which Weri and
Y79 cells were treated with control rabbit IgG and FITC or TRITC secondary antibodies. The adjacent bright-field images are also shown.
All images were taken at 40x. G: QPCR on canonical Wnt signaling receptors demonstrated higher expression of the receptors LRP6, Fz3,
Fz4, and Fz6 in the in ABCG2-positive (cancer stem-like cells) than ABCG2-negative (non-stem-like cells). Data are from two independent
experiments; each experiment had three replicates.
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4163%  relative  to  scrambled  siRNA,  n=4)  resulted  in  80%
increase in Oct3/4 expression (range: 30%–130% increase,
n=4), similar to the effect of LiCl (see Figure 1B). Expression
of Nanog was increased by approximately 20% by the SFRP2
siRNA. Total β-catenin levels were used as a measure of
canonical Wnt signaling, as shown previously in the Weri and
Y79 cell lines [24]. Western blotting of β-catenin in cells
transfected  with  siRNA  targeting  SFRP2  showed  a  38%
increase (data not shown). The small increase in β-catenin
levels may be due to the baseline Wnt signaling levels being
low  in  these  cell  lines  [24]  such  that  disinhibition  by
suppressing SFRP2 does not result in substantial increases.
In  conclusion,  the  number  of  cells  with  a  stem-like
phenotype  in  retinoblastoma  cell  lines  was  increased  by
treatment with LiCl and by reducing the expression of the
canonical Wnt pathway inhibitor SFRP2. These data suggest
that  canonical  Wnt  signaling  is  an  important  regulator  of
retinoblastoma stem-like cells in vivo.
DISCUSSION
Retinoblastoma is a retinal tumor that is proposed to derive
from pluripotent progenitor cells [37]. Wnt signaling is a
likely candidate pathway for playing a regulatory role in stem-
like cells in retinoblastoma tumors because of its function in
proliferation  and  differentiation  of  non-neoplastic  stem/
progenitor cells in the retina. The ciliary marginal zone (CMZ)
at the periphery of the retina in fish and amphibians contains
progenitor cells that have stem cell properties, including self-
renewal  and  multipotency  [38].  In  birds,  the  CMZ  stem/
progenitor cells are also proliferative but have more limited
differentiation capacity. In the analogous region in mammals,
the  pigmented  ciliary  margin,  stem/progenitor  cells  are
believed to be quiescent in vivo and act like stem cells when
cultured in vitro [39,40]. Activation of the canonical Wnt
pathway  in  chick  and  mouse  retinal  stem/progenitor  cells
promotes proliferation and inhibits neuronal differentiation
[30,32,33], whereas Wnt signaling promotes neurogenesis in
Xenopus retina CMZ [28]. Wnt signaling also increases the
number  of  microspheres  generated  from  the  mammalian
pigmented  ciliary  margin  [36,41],  suggesting  that  Wnt
signaling also maintains the stem cell population in mammals.
Furthermore, Wnt signaling was proposed to activate stem cell
properties  in  Muller  glia  and  promote  their  proliferation
during  retinal  injury  [36,42].  Our  data  suggest  that  the
postembryonic  role  of  Wnt  in  neoplastic  stem  cells  may
recapitulate its embryonic function as a mitogenic regulator
of stem/progenitor cells during retinal development.
Wnt signaling has been implicated as a stem cell growth
factor  in  several  cancer  types  [16,43,44].  Mutations  that
activate the Wnt pathway are suggested to cause constitutive
renewal and expansion of the stem cell pool, or to confer a
stem cell phenotype (renewal) to the progenitor cell pool
[16,44,45].  Future  studies  will  investigate  whether  the
increased numbers of stem-like cells that we observed in the
retinoblastoma cell lines are due to proliferation of existing
stem cells and/or conversion of nonstem cells to stem-like
cells. Another interesting observation was the difference in
receptor levels and stem cell marker genes between the cell
lines, with Y79 cells having a greater response. An intriguing
possibility is that the different responses may correlate with
differential metastatic potential of these cell lines [46].
In the present study, we used cell lines to perform basic
characterizations of the response of stem-like cells to LiCl,
based on previous findings of low but consistent levels of
stem-like cells in the human retinoblastoma tissue and cell
lines  [13,14].  Cell  lines  offer  the  convenience  of  large
numbers  of  cells  to  analyze:  they  do  not  require
vascularization and specific systemic requirements of solid
tumors in vivo, and are unlikely to be contaminated by non-
neoplastic  stem  cells  [47].  Because  the  cell  lines  are
maintained in culture for long periods, they are unlikely to
completely  represent  the  tumor  phenotype.  However,  cell
lines are useful for generating questions that can subsequently
be addressed in vivo.
LiCl was used in this study because it had a greater effect
on cell cycle arrest and viability in the retinoblastoma cell
lines than the canonical Wnt ligand Wnt3a [24]. Although
generally  used  to  activate  canonical  Wnt  signaling  by
inhibiting GSK3β, LiCl can also activate non-Wnt pathways
[48]. Furthermore, GSK3β itself mediates several signaling
pathways  [49],  and  regulates  the  hematopoietic  stem  cell
repopulation  through  the  Wnt,  Notch,  and  Hedgehog
pathways [50]. Unfortunately, using a Wnt ligand to activate
Wnt signaling produced inconsistent results, and we were
unable to compare with the response to LiCl. Our findings of
increased nuclear β-catenin and elevated Wnt ligands in the
Figure 5. Cancer stem-like cells have active Wnt signaling in the
retinoblastoma  cell  lines.  The  percent  of  co-localized  Msi1  and
nuclear β-catenin was quantified in the Weri and Y79 cell lines.
Immunohistochemistry demonstrated that tumor stem cells (Msi1+)
were more often positive for nuclear β-catenin than non-stem cells
(Msi-), indicating active Wnt signaling. The difference in nuclear β-
catenin was statistically significant at p<0.001 (*). The experiment
was repeated five times.
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42stem-like cells, and the results from knocking down SFRP2
to activate the Wnt pathway, suggest that Wnt signaling is
involved in regulating the number of stem-like cells in the
retinoblastoma cell lines. The possibility remains that LiCl
also acts through additional molecular pathways. Identifying
other LiCl-regulated signaling pathways that control survival
and  proliferation  of  retinoblastoma  stem-like  cells,  and
elucidating pathways that cross-talk with the Wnt pathway,
will be the focus of future studies.
SFRP2 antagonizes the canonical Wnt/β-catenin pathway
by acting as a decoy receptor for Wnt ligands and prevents
their interaction with the co-receptor Frizzled. Our results
suggest  that  SFRP2  is  downregulated  by  LiCl,  and  its
Figure 6. The Wnt inhibitor SFRP2 regulates cancer stem-like cells.
A: The Wnt inhibitor SFRP2 was decreased in Weri and Y79 cells
by addition of LiCl, as measured by QPCR on unsorted cells. The
difference  between  20  mM  and  40  mM  LiCl  was  statistically
significant at p<0.05 (*) and the difference between treated and
untreated was statistically significant at p<0.01 (**). The experiment
was repeated four times. B: Reducing SFRP2 levels using siRNA
(average  %  reduction  was  63%  relative  to  scrambled  siRNA)
increased stem cell marker gene expression. The increase in Oct3/4
expression was statistically significant at p=0.05 (*). The experiment
was repeated four times.
expression may antagonize maintenance of the stem-like cell
population. SFRP2 is an attractive candidate molecule for
controlling stem cell proliferation in retinoblastoma tumors in
vivo. SFRP2 is expressed during retinal development [51] and
regulates differentiation in non-neoplastic stem cells in the
retina [52], cardiomyocytes [53], and the pluripotent mouse
embryonal  carcinoma  stem  cell  line  P19CL6  [53].
Interestingly, SFRP2 increases as retinal stem/progenitor cells
differentiate into ganglion cells, which was associated with
decreased Wnt signaling [52]. In contrast, in the stem cell line
P19CL6, SFRP2 maintained the cells in an undifferentiated
state [53]. SFRP2 is also a tumor suppressor in many cancer
types, including colorectal, cervical, breast, and ovarian, and
is inactivated by hypermethylation of its promoter [54].
The response to Wnt signaling activators in a given tissue
is dependent on the intersection of other signaling pathways,
and can vary in the same cell population over time. Our data
suggest that Wnt signaling has two mechanisms of action in
retinoblastoma, and emphasizes the heterogeneous nature of
the response of tumors and tumor cell lines. In the current
study, we demonstrated that the Wnt signaling activator LiCl
increased the number of stem-like cells. In our previous work,
we showed that Wnt signaling (induced by LiCl and Wnt3a
ligand) has tumor suppressor properties in retinoblastoma and
induces cell cycle arrest in retinoblastoma cell lines [24].
Therefore, these data suggest that the growth of the bulk of
the tumor is halted by Wnt signaling whereas the stem-like
cells expand. Future work will investigate the basis of the
differential  response  to  Wnt  signaling.  A  therapy  that
decreases the bulk of the retinoblastoma tumor using Wnt
activator proteins would need to be used in combination with
inhibitors of the Wnt pathway that are specifically targeted to
the stem cell population, potentially by using ABCG2 or other
cancer stem cell marker genes.
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